Table 1.
Patient characteristics
| Characteristic | Group A (N = 1828) | Group B (N = 227) | Group C (N = 659) | Group D (N = 80) |
|---|---|---|---|---|
| Median age, years (range) | ||||
| All | 67 (50–81) | 71 (54–83) | 71 (57–84) | 73 (61–85) |
| Female | 68 (50–82) | 68 (55–84) | 72 (57–84) | 75 (47–81) |
| Male | 67 (51–81) | 71 (54–83) | 70 (58–84) | 72 (61–86) |
| Sex | ||||
| Female | 604 (33.0) | 60 (26.4) | 150 (22.8) | 12 (15.0) |
| Male | 1224 (67.0) | 167 (73.6) | 509 (77.2) | 68 (85.0) |
| Smoking habit | ||||
| Never smoked | 738 (40.7) | 100 (44.1) | 223 (34.0) | 21 (26.6) |
| Current smoker | 98 (5.4) | 9 (4.0) | 26 (4.0) | 2 (2.5) |
| Ex-smoker | 978 (53.9) | 118 (52.0) | 406 (62.0) | 56 (70.9) |
| GAP score | ||||
| I | 580 (49.7) | 48 (30.0) | 153 (36.2) | 13 (23.2) |
| II | 479 (41.0) | 96 (60.0) | 210 (49.6) | 36 (64.3) |
| III | 108 (9.3) | 16 (10.0) | 60 (14.2) | 7 (12.5) |
| Comorbidities | ||||
| 0 | 228 (12.5) | 9 (4.0) | 9 (1.4) | 0 (0.0) |
| 1 | 416 (22.8) | 18 (7.9) | 55 (8.3) | 3 (3.8) |
| 2 | 394 (21.6) | 36 (15.9) | 110 (16.7) | 6 (7.5) |
| > 2 | 790 (43.2) | 164 (72.2) | 485 (73.6) | 71 (88.8) |
| Antifibrotic treatment | ||||
| Pirfenidone | 589 (32.2) | 86 (37.9) | 220 (33.4) | 38 (47.5) |
| Nintedanib | 465 (25.4) | 31 (13.7) | 161 (24.4) | 16 (20.0) |
| No antifibrotic treatment | 774 (42.3) | 110 (48.5) | 278 (42.2) | 26 (32.5) |
Data are presented as n (%) or median (5th–95th percentile) unless otherwise indicated
GAP gender, age, and physiology